Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVERCOME: Colistin Monotherapy vs. Combination in XDR-GNB
NCT01597973Phase 3Completed
- Sponsor
- University of Michigan
- Start
- Oct 2012
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in pneumonia and bloodstream infection (BSI) comparing Colistin + Meropenem with Colistin + Placebo (2 arms). Primary endpoint: Mortality up to 4 weeks. Started Oct 2012; status: completed.
02
Drugs
meropenem
03
Conditions
pneumoniabloodstream infection (BSI)
Beyond the preview
Go deeper on NCT01597973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01597973.